# Special Issue

## Novelty in the Management of Progression and Complications of CKD

## Message from the Guest Editor

Proteinuria and elevated blood pressure (BP) are still the most significant risk factors determining the progression of CKD; thus, their treatment are of paramount importance in CKD management. Blockers of the renin-angiotensin system (RAS) are still recommended as the first-line treatment in all CKD hypertensive patients; however, their nephroprotective efficacy is less relevant in non-proteinuric patients. Given that RAS blockers can cause acute derangements in kidney function and hyperkalemia, caution is needed regarding their use, especially in frail, elderly nephroangiosclerotic patients or in the presence of advanced CKD. Dietetic-nutritional therapy (DNT) is an important component in conservative CKD management and should precede and be integrated in pharmacological treatment. Gliflozin is a very promising drug which has recently been approved not only for the treatment of diabetic nephropathy but for other causes of CKD and heart failure as well. The association of angiotensin II receptor antagonist with anti-endothelin I could be an interesting therapeutic approach for the near future.

## **Guest Editor**

Prof. Dr. Francesco Locatelli

Former Director, Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, 23900 Lecco, Italy

## Deadline for manuscript submissions

closed (30 May 2024)



# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



## mdpi.com/si/131748

Journal of Clinical Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcm@mdpi.com

mdpi.com/journal/

jcm





# Journal of Clinical Medicine

an Open Access Journal by MDPI

Impact Factor 2.9 CiteScore 5.2 Indexed in PubMed





## **About the Journal**

## Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine*'s (*JCM*) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

## **Editors-in-Chief**

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000 Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of Tokyo, Tokyo, Japan

## **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).